Bruce C Green

Author:

Bruce A. Green

ISBN #:

0823213285

Author:

Bruce Green

ISBN #:

0895530716

US Patent:

7285281, Oct 23, 2007

Filed:

Jun 5, 2002

Appl. No.:

10/478307

Inventors:

Bruce A. Green - New City NY, US
Randall K. Holmes - Golden CO, US
Michael G. Jobling - Aurora CO, US
Duzhang Zhu - Pomona NY, US

Assignee:

Wyeth Holdings Corporation - Madison NJ
The Regents of the University of Colorado, A Body Corporate - Aurora CO

International Classification:

A61K 39/106
C97K 1/00

US Classification:

4242611, 530350

Abstract:

Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

US Patent:

7332174, Feb 19, 2008

Filed:

Jun 5, 2002

Appl. No.:

10/478308

Inventors:

Bruce A. Green - New City NY, US
Randall K. Holmes - Golden CO, US
Michael G. Jobling - Aurora CO, US
Duzhang Zhu - Pomona NY, US

Assignee:

Wyeth Holdings Corporation - Madison NJ
The United States of America as represented by the Uniformed Services University of Health Sciences - Washington DC

International Classification:

A61K 39/106
C07K 1/00

US Classification:

4242611, 530350, 4242031, 4242011

Abstract:

Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

US Patent:

7615229, Nov 10, 2009

Filed:

Mar 13, 2003

Appl. No.:

10/507786

Inventors:

Bruce A. Green - New City NY, US
Gary W. Zlotnick - New Windsor NY, US
Leah D. Fletcher - Geneseo NY, US
Arnold L. Smith - Mercer Island WA, US
Thomas J. Reilly - Columbia MO, US

Assignee:

Wyeth Holdings Corporation - Madison NJ
The Curators of the University of Missouri - Columbia MO

International Classification:

A61K 39/02

US Classification:

4242561, 4242821, 4241931, 4241921, 4241851, 530350

Abstract:

A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination with additional antigens, are also provided.

US Patent:

7658931, Feb 9, 2010

Filed:

Dec 19, 2007

Appl. No.:

11/960226

Inventors:

Bruce A. Green - New City NY, US
Randall K. Holmes - Golden CO, US
Michael G. Jobling - Aurora CO, US
Duzhang Zhu - Pomona NY, US

Assignee:

Wyeth Holdings Corporation - Madison NJ
The United States of America, as represented by the Uniformed Services University of Health Sciences - Washington DC

International Classification:

C07K 14/28
A61K 39/106

US Classification:

4241901, 4242821, 435243, 435 693, 4353201, 530350, 536 237

Abstract:

Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

US Patent:

7666626, Feb 23, 2010

Filed:

Dec 17, 2008

Appl. No.:

12/336995

Inventors:

Bruce A. Green - New City NY, US
Gary W. Zlotnick - New Windsor NY, US
Leah D. Fletcher - Geneseo NY, US
Arnold L. Smith - Mercer Island WA, US
Thomas J. Reilly - Columbia MO, US

Assignee:

Wyeth Holdings Corporation - Madison NJ
The Curators of the University of Missouri - Columbia MO

International Classification:

C12P 21/06

US Classification:

435 691, 536 231, 536 237, 536 241, 4353201, 435 711, 435243, 4352523

Abstract:

A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination with additional antigens, are also provided.

US Patent:

8114417, Feb 14, 2012

Filed:

Aug 31, 2006

Appl. No.:

11/513417

Inventors:

Bruce A. Green - New City NY, US
Amy W. Masi - Caledonia NY, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

A61K 39/09
A61K 39/02
C07H 21/04
C12N 15/00
C12N 15/09

US Classification:

4242441, 4242341, 4241801, 4241901, 536 237, 4353201, 435 693

Abstract:

The present invention discloses amino acid sequences and nucleic acid sequences relating to a surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to compositions for the treatment and prophylaxis of infection or inflammation associated with bacterial infection.

US Patent:

8124750, Feb 28, 2012

Filed:

Aug 31, 2006

Appl. No.:

11/513418

Inventors:

Bruce A. Green - New City NY, US
Amy W. Masi - Caledonia NY, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

C07H 21/04
C12N 15/00
C12N 1/20
A61K 39/02
A61K 39/09

US Classification:

536 237, 536 231, 4353201, 4352521, 4242341, 4242441

Abstract:

The present invention discloses amino acid sequences and nucleic acid sequences relating to a surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to compositions for the treatment and prophylaxis of infection or inflammation associated with bacterial infection.

US Patent:

8568735, Oct 29, 2013

Filed:

Jun 22, 2010

Appl. No.:

13/379216

Inventors:

Annaliesa Anderson - Upper Saddle River NJ, US
Viliam Pavliak - Montebello NY, US
Kathrin Ute Jansen - Allendale NJ, US
Ingrid Lea Scully - Cornwall NY, US
Steven Morris Baker - Springwater NY, US
Jasdeep Singh Nanra - Suffern NY, US
Ellen Murphy - City Island NY, US
Bruce Arthur Green - New City NY, US
Mark Edward Ruppen - Garnerville NY, US
Yekaterina Timofeyeva - Mahwah NJ, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

A61K 39/085
A61K 39/40

US Classification:

42419711, 4241651, 4242431

Abstract:

The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from. The present invention also relates to immunogenic compositions, comprising capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against using immunogenic compositions of the polypeptides and capsule polysaccharides.